Good morning, Jason Mast here filling in for Ed. There are many types of coffee in this world and I must admit to you that I, preternaturally lazy and languorous, have become partial to instant. Don’t tell Ed, as I’m sure he will find it heresy. But I would point out that much of the world is on my side. Anyway, here’s some news. …
A closely watched experimental Alzheimer’s treatment may have failed because it simply didn’t do its job, STAT writes. A few weeks ago, less than two months after Eisai and Biogen said their amyloid-clearing Alzheimer’s drug significantly slowed patients’ decline, Roche announced that its own rival amyloid-clearing drug didn’t. At an Alzheimer’s conference yesterday, researchers got a peak at what may have driven the difference: Roche’s drug, gantenerumab, simply cleared far less amyloid. The data add credence to the idea that therapies have to mobilize a lot of amyloid before patients see an effect.
A startup will seek FDA approval for an over-the-counter nasal swab version of naloxone, the common opioid-reversal medication, the Wall Street Journal heralds. The move comes after a trial showed the swab exposed patients to more of the drug more quickly than the nasal spray version, and it comes as the FDA has asked companies to push for over-the-counter versions of the drug, amid an opioid crisis that has only worsened with the pandemic. The startup, Pocket Naloxone Corp., said it will apply for approval in the first half of next year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect